Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca

NEXT STORY
Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing Development of a New Class of Antibiotics Targeting Multi-Drug Resistant Gram-Negative Pathogens
PREV STORY
Robert F. Kennedy Human Rights Celebrates Five Courageous Humanitarians at its Star-Studded 2020 Ripple of Hope Award Ceremony
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting

Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve ...

author_avatar
NASDAQ Market News

Roche presents positive phase III study results for one-dose Xofluza in children with flu

author_avatar
NASDAQ Market News

Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA

author_avatar
NASDAQ Market News